|Bid||23.25 x 900|
|Ask||23.52 x 900|
|Day's Range||23.45 - 24.34|
|52 Week Range||13.63 - 35.31|
|Beta (5Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.21|
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present share price of $20.77.
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
It's been a sad week for Nektar Therapeutics (NASDAQ:NKTR), who've watched their investment drop 12% to US$20.81 in...
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019.
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Howard Robin became the CEO of Nektar Therapeutics (NASDAQ:NKTR) in 2007. This analysis aims first to contrast CEO...